Targeting IL-2 effect on regulatory T (Treg) cells is used in several immune-related diseases, including chronic graft-versus-host disease (cGVHD), type 1 diabetes (T1D), and systemic lupus erythematosus (SLE) [51]. This evidence concerns the gene IL2 and systemic lupus erythematosus.